Relay Therapeutics's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Relay Therapeutics (NASDAQ:RLAY) is scheduled to release its quarterly earnings report on February 22, 2024, with an estimated EPS of $-0.73. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for future growth. Relay Therapeutics has a history of beating EPS estimates, which has sometimes led to an increase in share price. However, the stock has seen a 41.42% decline over the last 52 weeks, indicating long-term shareholders might be concerned. The upcoming earnings report and guidance will be critical for the stock's short-term performance.
February 21, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Relay Therapeutics is anticipated to report an EPS of $-0.73 for the upcoming quarter. Historical performance shows potential for a positive reaction if earnings beat expectations and positive guidance is provided. However, the stock has experienced a significant decline over the past year, indicating potential investor concern.
The anticipation of Relay Therapeutics' earnings report and its potential to beat the EPS estimate could lead to short-term price volatility. Given the company's history of beating EPS estimates and the subsequent positive share price reactions, there's potential for a short-term positive impact if the trend continues. However, the significant annual decline in stock price and the importance of forward guidance introduce uncertainty, making the short-term impact neutral until the actual earnings and guidance are revealed.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100